{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:46:54Z","timestamp":1778856414953,"version":"3.51.4"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"5","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>In this issue, Paiva and colleagues characterize the dynamics of minimal residual disease (MRD) and clinical responses during chimeric antigen receptor (CAR) T-cell therapy of relapsed\/refractory multiple myeloma. Although both correlate with prolonged progression-free survival, MRD is reached faster in the bone marrow than complete response in peripheral blood; consequently, the study addresses the need for future guidelines to explore new MRD-negative definitions that are independent of the monoclonal (M) protein to overcome this limitation, particularly in clinical trials using early depth of response as an endpoint.<\/jats:p>\n                    <jats:p>See related article by Paiva et al., p. 365 (1).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0134","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T04:07:35Z","timestamp":1693541255000},"page":"346-348","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"first","affiliation":[{"name":"1Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-0917","authenticated-orcid":false,"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[{"name":"1Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"2025112416580055700_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2025112416580055700_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025112416580055700_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jmoldx.2020.10.015","article-title":"Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high-sensitivity flow cytometry","volume":"23","author":"Ho","year":"2021","journal-title":"J Mol Diagn"},{"key":"2025112416580055700_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112416580055700_bib5","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025112416580055700_bib6","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"2025112416580055700_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.18249","article-title":"Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma","volume":"198","author":"B\u00f6ckle","year":"2022","journal-title":"Br J Haematol"},{"key":"2025112416580055700_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2021015008","article-title":"Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"key":"2025112416580055700_bib9","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025112416580055700_bib10","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma","volume":"6","author":"Puig","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/4\/5\/346\/3360858\/346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/4\/5\/346\/3360858\/346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:58:09Z","timestamp":1764021489000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/4\/5\/346\/728658\/MRD-and-Plasma-Cell-Dynamics-after-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0134","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}